Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.
Frishberg Y, Hayes W, Shasha-Lavsky H, Sas DJ, Michael M, Sellier-Leclerc AL, Hogan J, Willey R, Gansner JM, Magen D. Frishberg Y, et al. Among authors: willey r. Front Pediatr. 2024 Sep 16;12:1392644. doi: 10.3389/fped.2024.1392644. eCollection 2024. Front Pediatr. 2024. PMID: 39355649 Free PMC article.
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.
Saland JM, Lieske JC, Groothoff JW, Frishberg Y, Shasha-Lavsky H, Magen D, Moochhala SH, Simkova E, Coenen M, Hayes W, Hogan J, Sellier-Leclerc AL, Willey R, Gansner JM, Hulton SA. Saland JM, et al. Among authors: willey r. Kidney Int Rep. 2024 Apr 26;9(7):2037-2046. doi: 10.1016/j.ekir.2024.04.048. eCollection 2024 Jul. Kidney Int Rep. 2024. PMID: 39081738 Free PMC article.
Designing black mirrors.
Willey RR. Willey RR. Appl Opt. 2024 May 20;63(15):4020-4023. doi: 10.1364/AO.523277. Appl Opt. 2024. PMID: 38856493
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D. Michael M, et al. Among authors: willey r. Am J Kidney Dis. 2023 Feb;81(2):145-155.e1. doi: 10.1053/j.ajkd.2022.05.012. Epub 2022 Jul 14. Am J Kidney Dis. 2023. PMID: 35843439 Free article. Clinical Trial.
The Family Network Collaborative: engaging families in pediatric critical care research.
Tamburro R, Pawluszka A, Amey D, Tomanio E, Coleman RW, Suttle M, Eaton A, Beers SR, Van KA, Grosskreuz R, October TW, DiLiberto MA, Willey R, Bisping S, Fink EL; CPCCRN and CPCCRN Family Network Collaborative. Tamburro R, et al. Among authors: willey r. Pediatr Res. 2023 Feb;93(3):453-456. doi: 10.1038/s41390-022-02048-1. Epub 2022 Jun 7. Pediatr Res. 2023. PMID: 35672385 Free PMC article. No abstract available.
Designing with very thin optical films.
Willey RR, Valavičius A, Goldstein FT. Willey RR, et al. Appl Opt. 2020 Feb 10;59(5):A213-A218. doi: 10.1364/AO.383929. Appl Opt. 2020. PMID: 32225386
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R, William WN Jr, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS. Ferrarotto R, et al. Among authors: willey r. Oral Oncol. 2018 Jul;82:83-90. doi: 10.1016/j.oraloncology.2018.05.014. Epub 2018 May 19. Oral Oncol. 2018. PMID: 29909907 Clinical Trial.
An SPR based sensor for allergens detection.
Ashley J, Piekarska M, Segers C, Trinh L, Rodgers T, Willey R, Tothill IE. Ashley J, et al. Among authors: willey r. Biosens Bioelectron. 2017 Feb 15;88:109-113. doi: 10.1016/j.bios.2016.07.101. Epub 2016 Jul 28. Biosens Bioelectron. 2017. PMID: 27503408
149 results